Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-102 in Platinum-Resistant Ovarian Cancer
NCT00806156Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2008
- Primary completion
- Oct 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of etirinotecan pegol in ovarian cancer (2 arms), sponsored by Nektar Therapeutics. Primary endpoint: Objective Response Rate by RECIST. Started Oct 2008; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00806156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806156.